Domainex's newsletter brings you up to speed on the latest announcements from the team.
No images? Click here
Domainex newsletter
All the latest news and industry insights from the Domainex team
The Domainex team has been busy since our last newsletter including opening our new Biology Centre of Excellence. The grand opening on the 7th February was officiated by Mrs Julie Spence OBE CStJ QPM, HM Lord-Lieutenant of Cambridgeshire, who also presented the King’s Award for Enterprise: International Trade 2023 to Domainex’s CEO, Dr Tom Mander.
Domainex launches Targeted Protein Degrader Toolbox
We have generated a toolbox consisting of approximately 160 partial degrader compounds (comprised of a linker and an E3 ligase binder). The toolbox is designed to be combined with Domainex’s Direct-to-Biology (D2B) platform for the rapid, plate-based synthesis of targeted protein degrader compounds.
Covalent fragment library ready for immediate screening
Targeted covalent inhibitors have the potential advantages of prolonged duration of action, improved potency and high levels of selectivity for the target of interest. Domainex's covalent fragment library, which includes a diverse range of warheads, is ready for immediate screening. Once hits are identified, our GSH reactivity counter-screen provides real time kinetics and we can identify the fragment binding site by performing protein digest and peptide mapping studies.
Domainex Invest in New Kit
We're pleased to announce that Domainex has invested in two pieces of brand new kit - the MBRAUN LABstar pro glovebox and the Biotage® V-10 Touch system to ensure that our services continue to deliver the highest levels of quality and efficiency using the latest technologies.
Drug Discovery and Development Exchange
Phil Rawlins, one of our biophysical assay experts will be presenting at the Drug Discovery and Development Exchange in London on June 11th about accelerating drug discovery projects for challenging targets
How Technological Trends are Helping Change the Drug Discovery Process
Our experts share their experiences with early compound characterization in the drug discovery process. Check out our latest blog.
Domainex and Unity Campus win CoStar UK Impact Award
The honour of the CoStar UK Impact Award for Lease of the Year 2024, was awarded for the work done by Howard Group to facilitate the bespoke development of our new facility with plenty of space to accommodate our recent growth and future plans.
Connecting with the life science industry
Our team have been out and about at a number of events in the last few months including meeting fellow life scientists at BioTrinity, presenting our latest progress at the Challenges in GPCR drug discovery workshop, heading to the US for Drug Discovery Chemistry, and much more. Check out our upcoming events to meet with us and learn more about our drug discovery research services.
A new life for CraftAbility's 60th Birthday
Domainex got in contact with CraftAbility to see if we could help the centre before its 60th birthday celebration. Our volunteer team consisting of six members from Domainex travelled from Sawston to Thaxted to help renovate the CraftAbility centre. Read more here.
New recruits
Welcome to Coral Munday, Gary Wu and Kyle Reid who have all recently joined the Domainex team.
Upcoming events
NanoTemper’s Drug Discovery & Development Exchange
11th June | London, UK
Milner Therapeutics Symposium 2024
2nd July | Cambridge, UK
ELRIG: Drug Discovery 2024
2nd October | London, UK
